| Click on "►" to expand:|
 BRAND NAMES
- Europe: Azopt PI, EMA summary for the public
- Italy: Azopt monografia
- U.S.: Azopt PI
 MECHANISM OF ACTION
Brinzolamide, is a carbonic-anhydrase inhibitor, an enzyme found in many tissues of the body, including the eye. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
Raised pressure inside the eye causes damage to the retina and to the optic nerve. This can result in serious loss of vision and even blindness. By lowering the pressure inside the eye, Brinzolamide reduces the risk of damage to these structures.
Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
One drop into the affected eye(s) three times daily. If more than one type of eye-drop medicine is being used, each one should be given at least 5-10 minutes apart.
When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.
 DOSAGE FORMS AND STRENGTHS
Solution containing 10 mg/mL Brinzolamide
- Hypersensitivity to any component of the product
- Hypersensitivity to sulfonamides
 WARNINGS AND PRECAUTIONS
- Brinzolamide is a sulfonamide and although administered topically is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. Patients should be advised that if serious or unusual reactions including severe skin reactions or signs of hypersensitivity occur, they should discontinue the use of the product.
- Acetazolamide (Diamox): Acetazolamide is an oral carbonic anhydrase inhibitor. Therefore, there is potential for an additive effect when taken with Brinzolamide (topically applied brinzolamide can be absorbed systemically).
 PREGNANCY AND LACTATION
- Pregnancy Category C (US). Brinzolamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Nursing Mothers: It is not known whether Brinzolamide is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
 SIDE EFFECTS
Most frequent adverse events were blurred vision, taste perversion (bitter, sour, or unusual taste), headache, blepharitis (inflammation of the eyelids), eye irritation, eye pain, dry eye, eye discharge, eye pruritus (itching), sensation of a foreign body in the eyes, ocular hyperaemia (red eye) and dry mouth
 RELATED LINKS